- Home
- RVI vs ETON Comparison
RVI vs ETON Comparison
Compare RVI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVI | ETON |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.4M | 872.7M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RVI | ETON |
|---|---|---|
| Price | $35.77 | $31.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 816.1K | 381.3K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | ★ N/A | $642.20 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $22.21 | $13.09 |
| 52 Week High | $77.39 | $35.66 |
Technical Indicators
Market Signals| Indicator | RVI | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 57.15 |
| Support Level | $24.27 | $16.17 |
| Resistance Level | $63.18 | $32.31 |
| Average True Range (ATR) | 4.50 | 1.74 |
| MACD | -2.29 | -0.06 |
| Stochastic Oscillator | 5.27 | 78.53 |
Price Performance
Historical ComparisonAbout RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.